INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,543,551 | +43.5% | 87,225 | +74.5% | 0.00% | 0.0% |
| Q2 2023 | $3,165,367 | -81.7% | 49,990 | -84.3% | 0.00% | -83.3% |
| Q1 2023 | $17,265,674 | +62461.3% | 318,849 | -38.9% | 0.01% | -25.0% |
| Q4 2022 | $27,598 | -99.9% | 521,502 | -28.6% | 0.01% | -38.5% |
| Q3 2022 | $34,005,000 | -21.0% | 730,882 | -3.0% | 0.01% | -13.3% |
| Q2 2022 | $43,026,000 | -5.6% | 753,768 | +1.2% | 0.02% | +7.1% |
| Q1 2022 | $45,577,000 | +10.3% | 744,880 | -5.7% | 0.01% | +16.7% |
| Q4 2021 | $41,338,000 | +51.6% | 789,819 | +8.0% | 0.01% | +33.3% |
| Q3 2021 | $27,267,000 | +10.0% | 731,479 | +20.4% | 0.01% | +12.5% |
| Q2 2021 | $24,794,000 | -6.7% | 607,434 | -22.4% | 0.01% | -11.1% |
| Q1 2021 | $26,567,000 | -29.1% | 783,031 | -33.5% | 0.01% | -35.7% |
| Q4 2020 | $37,454,000 | -5.7% | 1,177,771 | -23.9% | 0.01% | -17.6% |
| Q3 2020 | $39,725,000 | -3.2% | 1,548,152 | -3.2% | 0.02% | -5.6% |
| Q2 2020 | $41,058,000 | +63.4% | 1,599,493 | -2.2% | 0.02% | +38.5% |
| Q1 2020 | $25,130,000 | -56.9% | 1,634,982 | -3.9% | 0.01% | -38.1% |
| Q4 2019 | $58,373,000 | +344.4% | 1,701,373 | -3.2% | 0.02% | +320.0% |
| Q3 2019 | $13,135,000 | -40.8% | 1,758,347 | +2.9% | 0.01% | -44.4% |
| Q2 2019 | $22,189,000 | +12.2% | 1,709,500 | +5.3% | 0.01% | +12.5% |
| Q1 2019 | $19,771,000 | +20.2% | 1,623,196 | +12.4% | 0.01% | +14.3% |
| Q4 2018 | $16,450,000 | -46.6% | 1,444,223 | +1.7% | 0.01% | -41.7% |
| Q3 2018 | $30,813,000 | +28.5% | 1,419,888 | +4.7% | 0.01% | +20.0% |
| Q2 2018 | $23,974,000 | -4.8% | 1,356,720 | +13.4% | 0.01% | 0.0% |
| Q1 2018 | $25,194,000 | +35.7% | 1,196,860 | -6.6% | 0.01% | +25.0% |
| Q4 2017 | $18,563,000 | +25.3% | 1,281,975 | +36.5% | 0.01% | +33.3% |
| Q3 2017 | $14,817,000 | +84.3% | 938,980 | +45.1% | 0.01% | +50.0% |
| Q2 2017 | $8,038,000 | +296.9% | 647,187 | +419.3% | 0.00% | +300.0% |
| Q1 2017 | $2,025,000 | +214.4% | 124,622 | +192.2% | 0.00% | – |
| Q4 2016 | $644,000 | – | 42,653 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |